Learn about Eli Lilly's successful Phase 3 trial for orforglipron as a treatment for obesity and its potential impact on the pharmaceutical company and healthcare industry.
A closer look at the potential advantages of Eli Lilly's obesity pill, orforglipron, over its competitor Novo Nordisk's oral Wegovy.
Eli Lilly unveils a $6B Huntsville facility to manufacture APIs, creating ~450 jobs and boosting Alabama's pharma industry.
Eli Lilly announces plans to construct a new facility in Virginia with state-of-the-art technology and a capacity to produce various medicines, showing dedication to enhancing healthcare and advancing medical research.
